Medical Diagnostics

NG Biotech innovates and extends the technology through its patented platform allowing the development of real Quantitative and multiplex assays while most rapid test manufacturers are still working in a classical way developing qualitative assays for one target with a yes / no answer approach.


NG Biotech’s platform opens a new dimension with new opportunities; our competitive advantages are:

  • Detection of multiple cut-off values of diagnostic interest in 1 test format
  • Prolonged detection range
  • No high dose hook effect limitations
  • No cross reactivity interactions in multi-analyte sets
  • International patent pending platform
  • Generation of specific algorithms for instrument based quantification

In vitro medical devices for the examination of biological human specimens (whole blood, urine, saliva…) provide information on patient’s physiological condition. They represent an important activity of the health sector, 60 to 70% ¹ of medical decisions take into account an IVD result.

¹ The Lewing Group: The value of diagnostics: innovation, adoption and diffusion into health care, 2005


Diagnostics are improving patients’ healthcare management and reduce total healthcare expenditure. There is a general tendency to delocalize Diagnostics from the laboratory to the Point of Care; near the patient at the GP, Hospital bed side and even at home. The POC market with about 15% growth per year is foreseen to follow its path:

  • Rapid Diagnostic Tests are already part of healthcare cost cutting strategies.
  • There is a rapid movement of healthcare towards custom therapy and telemedicine. Future POC applications will be linked to the development of specific biomarkers that will answer whether or not a particular treatment is effective.
  • Health authorities will prioritize the reimbursement of new targeted therapies that include predictive and monitoring tools which are sensitive and easy to use.

NG Biotech is positioned on the Point of Care, also known as Rapid Test segment of the IVD medical market which covers multiple areas as Women’s Health, Cardiology, Oncology, Infectious disease, Drugs of abuse and Auto-Immune disease. Rapid IVDs are easy to perform in 1 or 2 steps. They generally provide results in less than 5 minutes from a direct analysis of specimen such as whole blood or urine; without instrumentation and specimen manipulation. Qualitative and Semi-Quantitative results can be read by the naked eye. Fully Quantitative results are obtained thanks to test adaptation to readers and dedicated algorithms.

  • Allow decentralized screening (outside the lab)
  • Ideal for population screening anywhere (HIV, Malaria…)
Early detection
  • Faster therapeutical decisions
  • Treatment at early stage
Immunization follow-up
  • Confirm vaccination effectiveness
Therapeutical monitoring
  • Monitor disease during and after treatment
Treatment effectiveness
  • Monitor patient response
Faster results
  • Urgent care optimisation
  • Faster patient management (primary Healthcare)
  • Reduction of hospitalization time
Early detection
  • Reduction of medical complications and terminal stage
Disease monitoring
  • Reduction of contamination pathways and the risk of contagion
  • Disease monitoring during and post treatment
Treatment effectiveness
  • Improvement of the effectiveness of selective treatment
  • Reduction of drug consumption
Mass screening
  • Increased access for a larger portion of the population to rapid diagnosis and monitoring
Self testing
  • Healthcare self management
  • Home testing
  • Increased opportunities for diagnostic applications
  • Onsite screening